Daiichi Sankyo (OTCMKTS:DSNKY) Posts Earnings Results, Beats Expectations By $0.05 EPS

Daiichi Sankyo (OTCMKTS:DSNKY) posted its quarterly earnings results on Thursday. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.05, Zacks reports. Daiichi Sankyo had a net margin of 15.40% and a return on equity of 18.39%. The firm had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.88 billion.

Daiichi Sankyo Stock Performance

Shares of OTCMKTS:DSNKY traded down $1.18 on Friday, hitting $18.20. The company’s stock had a trading volume of 959,665 shares, compared to its average volume of 428,224. Daiichi Sankyo has a 12 month low of $17.80 and a 12 month high of $28.21. The stock’s 50-day moving average is $21.81 and its two-hundred day moving average is $23.51. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.60 and a current ratio of 2.31. The company has a market capitalization of $34.48 billion and a price-to-earnings ratio of 17.17.

Analyst Ratings Changes

Separately, Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.